Estimating the percentage of European MSM eligible for PrEP: insights from a bio-behavioural survey in thirteen cities.
Por:
Cordioli M, Gios L, Huber JW, Sherriff N, Folch C, Alexiev I, Dias S, Nöstlinger C, Gama A, Naseva E, Valkovicová Staneková D, Marcus U, Schink SB, Rosinska M, Blondeel K, Toskin I and Mirandola M
Publicada:
1 nov 2021
Ahead of Print:
13 ene 2021
Resumen:
OBJECTIVES: This paper aims to estimate the percentage of European men who have sex with men (MSM) who may benefit from pre-exposure prophylaxis (PrEP), applying the three most widely used HIV risk indices for MSM (MSM Risk Index, Menza score, San Diego Early Test (SDET) score) and drawing on a large-scale multisite bio-behavioural survey (Sialon II). METHODS: The Sialon II study was a bio-behavioural survey among MSM implemented in 13 European cities using either time-location sampling or respondent-driven sampling. Biological and behavioural data from 4901 MSM were collected. Only behavioural data of HIV-negative individuals were considered. Three widely used risk indices to assess HIV acquisition risk among MSM were used to estimate individual HIV risk scores and PrEP eligibility criteria. RESULTS: 4219 HIV-negative MSM were considered. Regardless the HIV risk score used and the city, percentages of MSM eligible for PrEP were found to range between 5.19% and 73.84%. Overall, the MSM Risk Index and the Menza score yielded broadly similar percentages, whereas the SDET Index provided estimates constantly lower across all cities. Although all the three scores correlated positively (r>0.6), their concordance was highly variable (0.01
Filiaciones:
Cordioli M:
Infectious Diseases Section, Department of Diagnostics and Public Health, University of Verona, Verona, Italy
Huber JW:
School of Health Sciences, University of Brighton, Brighton, UK
Sherriff N:
School of Health Sciences, University of Brighton, Brighton, UK
:
Centre for Epidemiological Studies on Sexually Transmitted Infections and HIV/AIDS of Catalonia (CEEISCAT), Catalonia Public Health Agency (ASPCAT), Badalona, Spain - Biomedical Research Networking Centre in Epidemiology and Public Health (CIBERESP), Madrid, Spain
Alexiev I:
National Reference Confirmatory Laboratory of HIV, National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria
Dias S:
NOVA National School of Public Health, Public Health Research Centre, Comprehensive Health Research Centre, Universidade Nova de Lisboa, Lisboa, Lisboa, Portugal
Nöstlinger C:
Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium
Gama A:
NOVA National School of Public Health, Public Health Research Centre, Comprehensive Health Research Centre, Universidade Nova de Lisboa, Lisboa, Lisboa, Portugal
Naseva E:
Ministry of Health, Program "Prevention and control of HIV/AIDS", Sofia, Bulgaria
Valkovicová Staneková D:
NRC for HIV/AIDS Prevention, Slovak Medical University, Bratislava, Slovakia
Marcus U:
Department of Infectious Diseases Epidemiology, Robert Koch Institute, Berlin, Germany
Schink SB:
Department of Infectious Diseases Epidemiology, Robert Koch Institute, Berlin, Germany
Rosinska M:
Department of Infectious Disease Epidemiology and Surveillance, National Institute of Public Health-National Institute of Hygiene, Warszawa, Poland
Blondeel K:
Faculty of Medicine and Health Sciences, Ghent University, Gent, Belgium
UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland
Toskin I:
UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland
Mirandola M:
School of Health Sciences, University of Brighton, Brighton, UK
|